Merck KGaA (OTCMKTS:MKKGY – Get Free Report) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,771 shares, a decrease of 80.2% from the August 15th total of 8,948 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 98,007 shares, the days-to-cover ratio is currently 0.0 days.
Wall Street Analysts Forecast Growth
MKKGY has been the subject of a number of research reports. HSBC raised shares of Merck KGaA to a “hold” rating in a research report on Monday, July 6th. UBS Group downgraded Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Jefferies Financial Group initiated coverage on Merck KGaA in a research report on Tuesday, May 26th. They set a “hold” rating on the stock. Finally, Zacks Research downgraded Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Six analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Merck KGaA has a consensus rating of “Hold”.
View Our Latest Stock Report on MKKGY
Merck KGaA Stock Performance
Merck KGaA Company Profile
Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. Merck KGaA operates independently from the U.S.-based Merck & Co, Inc, which uses the name MSD in markets outside the United States and Canada.
The company operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, bioprocessing equipment and services used by academic institutions, pharmaceutical manufacturers and other industrial customers.
Further Reading
- Five stocks we like better than Merck KGaA
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
